Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06804837 · ClinicalTrials.gov registry record · NA

Implement and Test Visual Consent Template and Process

A NA study of Cancer and Alzheimer Disease, sponsored by Washington University School of Medicine.

Recruiting
Registry status
NA
Development phase
515
Enrollment target
3
Study locations

NCT06804837: Recruiting NA study of Cancer and Alzheimer Disease, sponsored by Washington University School of Medicine.

NCT06804837 is a NA study of Cancer and Alzheimer Disease that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 515 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06804837, a NA study of Cancer and Alzheimer Disease, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
NA
Development phase
515 participants
Enrollment target
3
Study locations

Study Summary

The investigators plan to conduct a stepped wedge randomized control trial to implement and test the consent template and process in three studies. Randomization will occur at the research coordinator/research team level. Each participating research team member will begin in the standard consent arm of the study. Subsequently, they will be randomized to the visual key information page arm at staggered time points to undergo training and begin using the visual key information page with patients who are eligible for the selected research study.

Primary Outcome

4 items on a Likert scale ranging from completely disagree to completely agree. Higher scores indicate greater feasibility. (1=completely disagree, 3= neither agree nor disagree, 5= completely agree)

Conditions Studied

Interventions

  • OTHER Visual consent
  • OTHER Standard consent

Study Locations (3)

Missouri

  • Washington University School of Medicine - St Louis

North Carolina

  • University of North Carolina at Chapel Hill School of Medicine - Chapel Hill

Utah

  • University of Utah Huntsman Cancer Institute (HCI) - Salt Lake City

Trial Details

FieldValue
Enrollment Target 515 participants
Start Date 2025-03-10
Est. Completion 2026-06-30
Phase NA

What NCT06804837 shows while recruiting

NCT06804837 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Visual consent is the first listed.

NCT06804837 reports a single indexed study location in Missouri, North Carolina, Utah.

Frequently Asked Questions

What is clinical trial NCT06804837 about?

NCT06804837 is a clinical study titled "Implement and Test Visual Consent Template and Process". The investigators plan to conduct a stepped wedge randomized control trial to implement and test the consent template and process in three studies. Randomization will occur at the research coordinator/research team level. Each participating research team member will begin in the standard consent arm...

What is the current status of trial NCT06804837?

This trial is currently recruiting. It is a NA study. The enrollment target is 515 participants. The study started on 2025-03-10. Estimated completion is 2026-06-30.

What conditions does trial NCT06804837 study?

This clinical trial studies the following conditions: Cancer, Alzheimer Disease.

What interventions are being tested in trial NCT06804837?

The interventions under investigation include: Visual consent (OTHER), Standard consent (OTHER).

Who is sponsoring clinical trial NCT06804837?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06804837 being conducted?

This trial has 3 study locations across Missouri, North Carolina, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06804837's enrollment target sits among peer trials

515 119th of 615 higher than 497 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05577819 · 515 participants · NA

    Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

  • NCT05933083 · 516 participants · NA

    MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

  • NCT05691244 · 514 participants · Phase 3

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

  • NCT06585488 · 514 participants · Phase 1

    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06804837, the US trial registry maintained by the National Library of Medicine. NCT06804837 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.